News for Bionano Genomics, Inc. (BNGO.MX)

Bionano Laboratories has revealed that a new Category I Current Procedural Terminology (CPT) code has been introduced by the American Medical Association's edit

**media[630265]**

Total Revenue: $6.5 million for Q1 2025, a decrease of 26% compared to Q1 2024.Flowcells Sold: 6,994 units in Q1 2025, a 15% decrease year-over-year; however,

**media[618060]**

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ( BNGO) today announced a peer-reviewed publication in Genome Research demonstrating that

Summary: Bionano Genomics (BNGO) forecasts significant revenue growth for 2025 with projections ranging between $29 and $32 million. Analyst price target

Quarterly Revenue: $8.2 million, surpassing the estimated $6.20 million.Quarterly EPS: Not provided, but compared to an estimated EPS of -6.00.Gross Margin: Im

Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsDavid Holmes - IRErik Holmlin - CEO and...

SAN DIEGO, and GREENWOOD, S.C., March 24, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ( BNGO) and Greenwood Genetic Center (GGC) today announced a publica

Featured Scientific Session: "Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory", an accredited continuin

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ( BNGO) today announced that it will host a conference call and live webcast on Monday, M

In-Motion Webinar: Bionano will host a webinar featuring the study's lead author, Dr. Guilin Tang, who will discuss the study and its findings in detail, includ

BD (BDX), a leading medical device company, experienced a significant stock movement with a 5.02% drop in its share price, reaching $232.77. The trading volume

Jin Medical International Ltd (ZJYL) experienced a notable stock movement with a 5.75% increase in its share price, reaching $0.980 per share. The trading volum

Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss

Preliminary Q4 2024 revenue expected to be between $7.9 and $8.1 million, which would represent an estimated decrease of approximately 25% over Q4 2023 due prim

Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ( BNGO) today announced the closing of its previously announced registered direct offering

**media[507427]**